Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Company Deals

Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion

Fineline Cube Nov 21, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...

Company Drug

US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment

Fineline Cube Nov 21, 2024

China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...

Company Drug

UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Nov 21, 2024

Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...

Company Deals

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies

Fineline Cube Nov 21, 2024

US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...

Legal / IP

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa

Fineline Cube Nov 21, 2024

China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...

Company Deals

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102

Fineline Cube Nov 20, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...

Company Drug

GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus

Fineline Cube Nov 20, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...

Company Drug

Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter

Fineline Cube Nov 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...

Company Deals

Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan

Fineline Cube Nov 20, 2024

Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...

Company Drug

MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial

Fineline Cube Nov 20, 2024

US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...

Company Deals

Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student

Fineline Cube Nov 20, 2024

French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of...

Company Medical Device

New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health

Fineline Cube Nov 20, 2024

Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of...

Policy / Regulatory

NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections

Fineline Cube Nov 20, 2024

The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...

Company Drug

Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV

Fineline Cube Nov 20, 2024

China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...

Posts pagination

1 … 308 309 310 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.